

THE GUT MICROBIOTA REVOLUTION: AN OVERVIEW OF FECAL MICROBIOTA TRANSPLANTATION FOR GASTROINTESTINAL DISORDERS

Dr. MIRSHAD PV

Pharmacology, MES Medical College, Perinthalmanna, Malappuram Kerala, India.

DEEPTHY KUNNATHULLY DINESH *

Lecturer, Biochemistry, College of Medicine, Imam Abdurrahman Bin Faisal University, Dammam, KSA, Saudi Arabia. * Corresponding Author Email: dkdinesh@iau.edu.sa

Dr. JEEJA MC

Pharmacology, MES Medical College, Perinthalmanna, Malappuram Kerala, India.

Dr. MUMTAZ P

Obstetrics, Gynecology, MES Medical College, Perinthalmanna, Malappuram, Kerala, India.

FATIMAH ALI SHAABI

Lab Tech, Biochemistry, College of Medicine, Imam Abdurrahman Bin Faisal University, Dammam KSA.
Email: fatto_a@yahoo.com

Abstract

The gut microbiota revolution has emerged as a significant breakthrough in understanding the intricate relationship between the microbial community residing in the human gut and its impact on various aspects of human health. Among the notable advances in this field, fecal microbiota transplantation (FMT) has gained considerable attention as a promising therapeutic approach for gastrointestinal disorders. This review provides an overview of FMT, its historical background, methodology, and its potential applications in the treatment of gastrointestinal disorders. FMT involves the transfer of fecal material with the aim of restoring a balanced and diverse gut microbiota. FMT is most commonly utilized for the management of recurrent *Clostridioides difficile* infection. Clinical studies investigating the efficacy of FMT have shown promising results, particularly in the management of recurrent *Clostridioides difficile* infection. The restoration of a healthy gut microbiota through FMT appears to promote microbial diversity, improve microbial functions, and modulate the host immune response. However, challenges remain, including standardization of the procedure, long-term safety monitoring, and optimizing donor selection and preparation protocols. In conclusion, fecal microbiota transplantation represents a revolution in the field of gut microbiota research and offers a promising therapeutic avenue for gastrointestinal disorders. While the evidence base continues to evolve, FMT holds significant potential to transform the management of various conditions by targeting the root cause of dysbiosis. Continued research and clinical trials are warranted to establish guidelines, refine protocols, and expand the applications of FMT in gastrointestinal medicine.

Keywords: Fecal Microbiota; Gastrointestinal Disorders; Transplantation

INTRODUCTION

The gut is home to a complex ecosystem of microorganisms that are crucial for maintaining good health. Disruptions to this ecosystem can lead to various gastrointestinal disorders. Fecal microbiota transplantation (FMT) has recently emerged as a potential therapy for these conditions. FMT involves transferring fecal matter from a healthy donor to the recipient's gastrointestinal tract in order to restore the balance of the gut microbiota. The treatment has gained significant attention due to its effectiveness in treating *Clostridioides difficile* infection (CDI) and inflammatory bowel disease (IBD). The CDI is a bacterial infection that causes diarrhea and is challenging to treat with antibiotics. FMT has shown a high success rate in treating recurrent CDI that has not responded to standard therapies. In a meta-analysis of 65 studies with over 8,000 patients, FMT had a 91% success rate in resolving CDI symptoms¹.

The FMT is now recommended for recurrent CDI treatment in several clinical practice guidelines. The IBD, a chronic inflammatory condition of the gastrointestinal tract, includes Crohn's disease and ulcerative colitis. Although research into FMT's potential for treating IBD is limited, a systematic review and meta-analysis of 31 studies showed that FMT resulted in a significant improvement in clinical remission rates compared to placebo or conventional treatment².

The FMT has also shown promise in treating other gastrointestinal disorders, including irritable bowel syndrome (IBS), characterized by abdominal pain and altered bowel habits. While evidence for FMT in IBS is still limited, a recent randomized controlled trial found that FMT was associated with a significant reduction in symptoms compared to placebo³.

Beyond its therapeutic potential, the FMT has sparked interest in microbiome research, as it provides an opportunity to study the role of the gut microbiota in health and disease. FMT has been used to explore the connection between the gut microbiota and non-gastrointestinal disorders, such as metabolic and neurological disorders, and even cancer⁴.

However, FMT's long-term safety and efficacy are not yet established, and there are concerns about the risk of infectious disease transmission from the donor. Further research is needed to address these concerns and establish FMT as a safe and effective therapy for gastrointestinal disorders⁵. Nonetheless, FMT has great potential to advance our understanding of the gut microbiota's role in health and disease and to offer an innovative treatment option for various gastrointestinal disorders. This review is aimed to discuss the status of FMT in modern medicine. It also discusses the regulatory status and its future applications.

HISTORY OF FMT

The FMT has a long history, with the practice of transplanting fecal matter for the treatment of gastrointestinal disorders dating back to ancient China. It was known as "yellow soup" and was used to treat a variety of ailments, including food poisoning and severe diarrhea. In the 16th century, fecal enemas were used by a Dutch physician to treat patients with constipation. However, as medical knowledge and technology advanced, the practice fell out of favor. The modern era of FMT began in the 20th century when several researchers revived interest in the procedure. In the 1950s, a surgeon named Ben Eiseman successfully used FMT to treat patients with pseudomembranous colitis. However, with the increasing availability and efficacy of antibiotics, the procedure was not widely adopted. In the 1990s, a Dutch gastroenterologist named Jan Terveer used FMT to treat patients with *Clostridium difficile* infection (CDI)⁶. This bacterial infection causes severe diarrhea and can be difficult to treat with antibiotics. FMT was found to be highly effective in treating CDI, with success rates of up to 90%. Since then, FMT has been studied and used to treat a variety of other conditions, including inflammatory bowel disease, irritable bowel syndrome, Parkinson's disease, and multiple sclerosis⁷.

Although FMT is still a relatively new procedure and more research is needed to fully understand its effectiveness and safety, it has shown promise as a treatment for a range of conditions. The long history of FMT and its recent resurgence demonstrate the potential benefits of harnessing the power of the gut microbiota to treat various gastrointestinal and non-gastrointestinal disorders⁸.

FMT in Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a chronic condition affecting the gastrointestinal tract, which includes Crohn's disease and ulcerative colitis. It is believed that IBD results from an abnormal immune response to the gut microbiome, leading to chronic inflammation and tissue damage. The use of FMT has been suggested as a potential treatment for IBD, as it can restore the balance of the gut microbiota⁹.

Clinical trials have been conducted to evaluate the safety and efficacy of FMT in treating IBD. A randomized controlled trial published in the *New England Journal of Medicine* in 2013 found that FMT induced remission in patients with recurrent *C. difficile* infection and IBD. Another randomized controlled trial published in 2016 demonstrated that FMT was more effective than placebo in inducing remission in patients with ulcerative colitis¹⁰.

One of the main advantages of the FMT in treating IBD is that it offers a targeted approach to the disease by restoring the balance of the gut microbiome. Unlike conventional drugs that have systemic effects, FMT specifically targets the root cause of the disease. By introducing healthy microbes from a donor's stool into the patient's gut, FMT can reduce inflammation, improve symptoms, and potentially achieve long-term remission¹¹. Despite the promising results of FMT in treating IBD, there are still many questions that need to be answered before it can be widely used as a therapy. For instance, it is unknown how

long the effects of FMT last, and whether repeated treatments are necessary to maintain remission. In addition, safety concerns remain, particularly with regard to transmitting infectious diseases from the donor to the recipient¹². While FMT for IBD is still considered an experimental therapy, ongoing clinical trials are evaluating its safety and efficacy. The FDA has not yet approved FMT for the treatment of IBD, but it has issued safety alerts and guidelines related to the procedure. With further research and development, FMT may eventually become a mainstream treatment option for patients with IBD. However, the challenges of identifying suitable donors and ensuring the safety of the procedure must be addressed, and the optimal dosing and frequency of FMT for IBD have yet to be established¹³.

FMT in *Clostridioides difficile* Infection

Clostridioides difficile, a gram-positive, spore-forming bacterium, is known to cause diarrhea and colitis in patients who have received antibiotics. These drugs can disrupt the gut microbiota, creating an environment favorable to the colonization and growth of *C. difficile*. FMT has been successful in treating CDI, as it restores a healthy gut microbiota that outcompetes *C. difficile* for resources in the gut. FMT can be administered via different routes such as colonoscopy, nasogastric tube, or enema, with cure rates of over 90% and a low risk of adverse events¹⁴.

Several considerations must be taken when performing the FMT, including the screening of donors, preparation of fecal material, and administration technique. Donors should undergo testing for infectious diseases and other risk factors, and fecal material should be processed and screened for safety and efficacy¹⁵. The administration technique should be chosen according to the individual patient's preferences and needs. In the United States, FMT is classified as an investigational drug by the FDA and can be used under an investigational new drug (IND) application, with guidance on donor screening, testing, informed consent, and labeling requirements¹⁶.

In 2020, the FDA issued a safety alert regarding the use of FMT for CDI after two patients developed invasive infections caused by drug-resistant bacteria. Consequently, the FDA temporarily halted several clinical trials investigating the use of FMT for CDI. However, the suspension was lifted in 2021 after reviewing safety data, with additional screening and testing of donor stool for multidrug-resistant organisms as a condition¹⁷. Canada and the United Kingdom have different regulations regarding FMT, with Canada regulating it as a human cell, tissue, or organ product that can be used for the treatment of recurrent CDI with a physician's prescription. The United Kingdom considers FMT a medicine, and it is regulated by the Medicines and Healthcare products Regulatory Agency¹⁸.

In conclusion, FMT is a promising therapy for recurrent CDI, with further research required to determine optimal donor screening and preparation protocols and long-term safety and efficacy.

FMT in Irritable Bowel Syndrome

The cause of Irritable Bowel Syndrome (IBS) remains uncertain, but it is thought to involve a complex interaction between genetic, environmental, and psychosocial factors. However, research suggests that alterations in the gut microbiota may play a role in the development and symptoms of IBS. FMT has been proposed as a possible treatment for IBS¹⁹. The concept behind FMT for IBS is that transplanting fecal matter from a healthy donor into the gut of someone with IBS could help to restore a more balanced and diverse gut microbiota, leading to improved symptoms. Although small studies have shown mixed results, with some reporting relief in symptoms such as abdominal pain and bloating, others have not found significant benefits. One study found that FMT was more effective in patients with diarrhea-predominant IBS than in those with constipation-predominant IBS. Despite these mixed results, FMT is gaining interest as a potential IBS treatment, especially as more precise methods for identifying and characterizing the gut microbiota and improving FMT delivery become available²⁰.

It is important to note that FMT for IBS is an experimental treatment and is not approved by regulatory agencies such as the FDA or the European Medicines Agency. As with any experimental treatment, patients should discuss the potential risks and benefits with their healthcare provider before considering FMT for IBS²¹. Additionally, more research is necessary to fully understand the potential risks and benefits of FMT for IBS and identify which patients may benefit most from this treatment.

FMT in Metabolic Disorders

Current evidence indicates that FMT can improve metabolic parameters such as insulin resistance, inflammation, and glucose tolerance²². Nonetheless, the evidence remains limited and more research is required to fully understand the risks and benefits of FMT for metabolic disorders. In the United States, the FDA does not authorize the use of FMT for metabolic disorders, and it is considered experimental. Nevertheless, clinical trials investigating the application of FMT for metabolic disorders are ongoing, which may help determine its safety and efficacy in the future²³.

It is critical to understand that FMT does not replace healthy lifestyle habits such as a balanced diet and regular exercise, which are critical in managing metabolic disorders. Individuals with metabolic disorders should consult their healthcare provider about the potential benefits and risks of FMT before considering this treatment.

FMT in Neuropsychiatric Disorders

Neuropsychiatric disorders, including depression, anxiety, and autism spectrum disorder, have been investigated as potential targets for FMT. The gut microbiota has been linked to brain function and behavior through the gut-brain axis, which can be altered in patients with neuropsychiatric disorders²⁴. While some studies have reported improvements in symptoms such as depression and anxiety, others have not found significant benefits. However, there is growing interest in FMT as a potential treatment for these disorders, and advances in characterizing the gut microbiota and improving FMT delivery methods

may help to refine this approach. It is important to note that FMT for neuropsychiatric disorders is currently considered experimental and is not approved by regulatory agencies. Patients should discuss the potential risks and benefits with their healthcare provider before considering FMT, and more research is needed to fully understand its potential benefits and risks²⁵.

FMT in Allergic Disorders

The potential role of FMT in treating allergic disorders, such as food allergies, atopic dermatitis, and asthma, has been investigated in several small studies with mixed results. Some studies have reported improvements in symptoms, while others have not found significant benefits. Nonetheless, evidence suggests that changes in the gut microbiota may contribute to the development of allergic disorders, and that FMT may help to restore a healthier gut microbiota and improve immune function²⁶.

The FMT has shown promise in inducing tolerance to peanut allergen in children with peanut allergy, as well as improving symptoms of atopic dermatitis in some patients. However, its effectiveness in treating allergic disorders is still uncertain, and more research is needed to better understand the potential benefits and risks of this treatment²⁷.

Currently, FMT is not approved by the FDA for the treatment of allergic disorders in the United States, and its use is considered experimental. However, ongoing clinical trials are being conducted to investigate the safety and effectiveness of FMT for allergic disorders. Patients with allergic disorders should discuss the potential benefits and risks of FMT with their healthcare provider before considering this treatment option²⁸. With the development of more precise methods for identifying and characterizing the gut microbiota, and improvements in FMT delivery methods, FMT may become a more refined and effective treatment option for allergic disorders in the future²⁸.

FMT in Autoimmune Disorders

The FMT is being studied as a potential treatment for autoimmune disorders such as inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis. Research has shown that changes in the gut microbiota may be linked to the development and progression of autoimmune disorders, and that FMT may help to restore a healthier gut microbiota and improve immune function²⁹.

There have been several small studies investigating the use of FMT for autoimmune disorders, with mixed results. While some studies have reported improvements in symptoms and disease activity, others have not found significant benefits³⁰. For example, a study found that FMT was associated with improved disease activity in patients with ulcerative colitis, while another study found no significant differences in disease activity between patients who received FMT and those who received a placebo³⁰.

Despite these mixed results, interest in FMT as a potential treatment for autoimmune disorders is increasing. Refinements in the methods used to identify and characterize the

gut microbiota, as well as improvements in the delivery of FMT, may help to increase the effectiveness of this approach³¹.

The FMT is currently considered experimental in the United States, and is not approved by the FDA for the treatment of autoimmune disorders. However, ongoing clinical trials are investigating the use of FMT for autoimmune disorders, which may help to determine its safety and effectiveness in the future. Patients with autoimmune disorders should consult with their healthcare provider before considering FMT, as there may be potential risks and benefits to this treatment³².

CHALLENGES IN FMT

The FMT is a promising therapy for a range of gastrointestinal and non-gastrointestinal conditions. Despite its potential benefits, several barriers, challenges, and limitations are associated with this procedure³³.

One of the primary safety concerns is the risk of transmitting infectious diseases, including bacteria, viruses, fungi, and parasites. While donors and stool samples undergo rigorous screening, there is still a possibility of transmitting unknown or novel pathogens.

Another issue is the lack of standardization in FMT procedures, including donor screening, stool preparation, and delivery methods. This variability can lead to differences in safety and efficacy outcomes, and hinder the development of standardized protocols³⁴.

The FMT is currently available only at a limited number of specialized centers, which limits its accessibility to patients and hinders its integration into standard clinical practice.

Ethical considerations also arise with the use of fecal matter as a treatment, such as concerns regarding the use of human body products, privacy and confidentiality of donors, and informed consent of patients. The cost of FMT can also be a significant barrier for patients, as it is usually not covered by insurance and can be expensive³⁵.

Furthermore, limited research has been conducted on the long-term safety and efficacy of FMT. As a result, it is challenging to understand its potential benefits and risks fully and identify which patients are most likely to benefit from this treatment³⁵.

In conclusion, while FMT holds promise as a therapeutic intervention, there are significant barriers, challenges, and limitations that need to be addressed to improve its safety, efficacy, and accessibility.

FUTURE OF FMT

The FMT is an emerging therapy with the potential to treat a variety of gastrointestinal disorders, particularly recurrent *Clostridioides difficile* infection (CDI). However, ongoing research is needed to explore its potential uses and improve its safety and efficacy. One area of research focuses on developing more targeted approaches to FMT by delivering specific bacterial strains or microbial metabolites that are particularly important for treating certain conditions. Another area of research aims to develop less invasive delivery methods, such as fecal microbial capsules or enemas³⁶.

Furthermore, ongoing research is investigating the potential uses of FMT for other gastrointestinal disorders, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and nonalcoholic fatty liver disease (NAFLD). While early studies suggest that FMT may have some benefit for these conditions, further research is necessary to determine its safety and effectiveness³⁷.

Lastly, the safety of FMT is an important concern, as there is a risk of transmitting infectious diseases or other adverse events during the procedure. To improve safety, researchers are developing more rigorous donor screening protocols and testing methods³⁸.

In conclusion, FMT is a rapidly developing field with the potential to treat various gastrointestinal disorders. Ongoing research is focused on developing targeted and effective therapies, improving delivery methods, and ensuring the safety of the treatment.

CONCLUSION

The FMT has emerged as a promising therapy for a range of gastrointestinal disorders, particularly recurrent *Clostridioides difficile* infection. Over the past decade, FMT has gained wider acceptance in clinical practice, with several professional societies endorsing its use for certain conditions. However, FMT remains an experimental therapy, and regulatory agencies such as the FDA have not yet approved it for widespread use. Ongoing research is exploring new delivery methods, developing more targeted approaches, and improving the safety and efficacy of the treatment. The future of FMT is promising, and with continued research, it may become a standard therapy for certain gastrointestinal disorders in modern medicine.

References

- 1) Allegretti JR, Kassam Z, Carrellas M, Mullish BH, Marchesi JR, Pechlivanis A, et al. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. *Am J Gastroenterol.* 2019; 114(7):1071-9. 10.14309/ajg.0000000000000224. PMID: 31188198; PMCID: PMC6945486.
- 2) Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, et al. Fecal Microbiota Transplantation for Hepatic Encephalopathy: A Randomized Clinical Trial. *Gastroenterology.* 2018 Nov; 155(6):1702-1709.e8.
- 3) Lopez J, Grinspan AM, Fecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. *Journal of Clinical Gastroenterology.* 2019 Mar; 53(3):218-224.
- 4) Borody TJ, Nowak A, Finlayson S. The GI microbiome and its role in chronic bowel disorders. *Best Pract Res Clin Gastroenterol.* 2016 Dec; 30(6):725-37.
- 5) Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of IBS: a need for further studies. *Eur Rev Med Pharmacol Sci.* 2016 Nov; 20(21):4466-4471. PMID: 27874966.
- 6) Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, Putignani L, Fischer M, Keller JJ, Costello SP, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. *Gut.* 2019 Feb; 68(2):211-220.
- 7) Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. *Gut.* 2017; 66(4):569-580. doi:10.1136/gutjnl-2016-313017
- 8) DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, et al. Drug-Resistant *E. coli* Bacteremia Transmitted by Fecal Microbiota Transplant. *N Engl J Med.* 2019; 381(21):2043-50.
- 9) Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent *Clostridium Difficile* Infection. *Gastroenterology.* 2019; 156(5):1324-1332.e3.
- 10) Hourigan SK, Chen LA, Grigoryan Z, Laroche G, Weidner M, Sears CL, et al. Microbiome Changes Associated with a Single Early Fecal Microbiota Transplantation in a Patient with *Clostridium difficile* Infection and Autism Spectrum Disorder. *Open Forum Infectious Diseases.* 2019 Jun; 6(6):ofz215. doi: 10.1093/ofid/ofz215. PMID: 31198619.
- 11) Hvas CL, Dahl Jørgensen SM, Jørgensen SP, Storgaard M, Lemming L, Hansen MM, Erikstrup LT, Dahlerup JF. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent *Clostridium difficile* Infection. *Gastroenterology.* 2019 Jan; 156(1):132-141.e3. doi: 10.1053/j.gastro.2018.08.061. Epub 2018 Sep 5. PMID: 30193935.
- 12) Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, Goll R, Bjørnbeth BA, Grønbech JE, Røseth AG. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. *Lancet Gastroenterol Hepatol.* 2018 Mar; 3(3):17. doi: 10.1016/S2468-1253(18)30059-0. Epub 2018 Feb 8. PMID: 29428272.
- 13) Arasaradnam RP, Brown S, Forbes A, Fox MR, Hungin P, Kelman L, et al. Guidelines for the Investigation of Chronic Diarrhoea in Adults: British Society of Gastroenterology, 3rd edition. *Gut.* 2018 Jul;67(7):1380-1399.
- 14) Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for *Clostridium difficile* infection: systematic review and meta-analysis. *Am J Gastroenterol.* 2013 Apr; 108(4):500-8.

- 15) Kelly CR, Kahn S, Kashyap P, et al. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. *Gastroenterology*. 2015; 149(1):223-237.
- 16) Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G., & Dinan, T. G. (2017). Cross talk: the microbiota and neurodevelopmental disorders. *Frontiers in Neuroscience*, 11, 490.
- 17) Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. *Nat Rev Gastroenterol Hepatol*. 2016; 13(9):508-516. doi:10.1038/nrgastro.2016.98
- 18) Kuitunen M, Kukkonen K, Juntunen-Backman K, et al. Fecal microbiota transplantation for the treatment of atopic dermatitis in children: a randomized, placebo-controlled trial. *J Allergy Clin Immunol*. 2019; 143(3):1027-1030.e8.
- 19) Ma, Q., Xing, C., Long, W., Wang, H. Y., Liu, Q., Wang, R. F., & Xu, K. (2019). Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. *Journal of Neuroinflammation*, 16(1), 53. doi: 10.1186/s12974-019-1444-8.
- 20) Moayyedi P, Surette MG, Kim PT, et al. Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology*. 2015; 149(1):102-109.e6.
- 21) Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet*. 2017; 389(10075):1218-1228.
- 22) Paramsothy S, Nielsen S, Kamm MA, et al. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. *Gastroenterology*. 2019 Jan; 156(1):144-155.e8.
- 23) Paramsothy S, Nielsen S, Kamm MA, et al. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. *Gastroenterology*. 2019; 156(5):1440-1454.e4.
- 24) Allegretti JR, Fischer M, Li N, et al. Gut Microbial Biomarkers of Individualized Treatment Response in Patients with Gastrointestinal Disorders. *Clinical Gastroenterology and Hepatology*. 2020 Jul; 18(8):1795-1802.e7.
- 25) Paramsothy S, Paramsothy R, Rubin DT, et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. *J Crohns Colitis*. 2017; 11(10):1180-1199.
- 26) Paramsothy S, Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, et al. Faecal microbiota transplantation for inflammatory bowel disease: A systematic review and meta-analysis. *Journal of Crohn's and Colitis*. 2017 Nov 1; 11(11):1428-41.
- 27) Rokhlina T, Kenyon J, Brady M, et al. Fecal microbiota transplantation for treatment of recurrent *Clostridioides difficile* infection in pediatric patients: A systematic review of real-world experience. *J Clin Gastroenterol*. 2021; 55(3):201-207.
- 28) Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. *Gastroenterology*. 2015; 149(1):110-118.e4.
- 29) Rossen NG, MacDonald JK, de Vries EM, D'Haens GR, de Vos WM, Zoetendal EG, et al. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. *World J Gastroenterol*. 2015; 21(17):5359-71.
- 30) Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. *Gastroenterology*. 2013; 145(5):946-953.

- 31) US Food and Drug Administration. Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat *Clostridium difficile* Infection Not Responsive to Standard Therapies. 2021 Jun 17. Available from: <https://www.fda.gov/media/131926/download>.
- 32) US Food and Drug Administration. Fecal Microbiota for Transplantation: Safety Alert - Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms. 2020 Mar 12. Available from: <https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-reactions-due-transmission-multi>.
- 33) Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. *J Allergy Clin Immunol*. 2017; 139(1):173-181.e8.
- 34) Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F., ... & de Vos, W. M. (2012). Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology*, 143(4), 913-916.
- 35) Wang H, Braun C, Murphy EF, et al. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent *Clostridium difficile* Infection: A Randomized Trial. *Ann Intern Med*. 2018; 169(9):Epub ahead of print.
- 36) Xu MQ, Cao HL, Wang WQ, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. *World J Gastroenterol*. 2015 May 7; 21(17):102-11.
- 37) Xu MQ, Cao HL, Wang WQ, Wang S, Cao XC, Yan F, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. *World Journal of Gastroenterology*. 2015 Feb 28; 21(8):102–11.
- 38) Mostafa SHABAN, Huda Hamdy MOHAMMED, S.H. Role of Community Health Nurse in the Prevention of Elderly Dehydration: A Mini - Review. *J. Integr. Nurs.* **2022**, *4*, 166–171, doi:10.4103/jin.jin.
- 39) Zhang F, Cui B, He X, et al. Microbiota transplantation therapy improves gut dysbiosis and cognitive function in patients with drug-resistant epilepsy. *Epilepsy Behav*. 2020; 112:107286.